Video

Dr. Kim on the Investigation of Regorafenib in mCRC

Author(s):

Richard Kim, MD, medical oncologist, Gastrointestinal Oncology Department at Moffitt Cancer Center, discusses studies investigating regorafenib (Stivarga) in metastatic colorectal cancer.

Richard Kim, MD, medical oncologist, Gastrointestinal Oncology Department at Moffitt Cancer Center, discusses studies investigating regorafenib (Stivarga) in metastatic colorectal cancer (mCRC).

Regorafenib is an oral multikinase inhibitor approved for use in patients with mCRC following progression after prior therapy. The results of the phase III CORRECT trial showed improvement in progression-free survival (PFS) and overall survival (OS).

In the trial, patients in the regorafenib cohort had a median OS of 6.4 months versus 5.0 months in the placebo arm (hazard ratio [HR] = 0.77; 95% CI, 0.64—0.94; P = .0052). The regorafenib arm experienced a median PFS of 1.9 months versus 1.7 months in the placebo arm (HR = 0.49; 95% CI, 0.42—0.58; P < .000001).

The next step, Kim says, is to move regorafenib to the second-line setting in combination with the chemotherapy regimen FOLFIRI (leucovorin calcium, fluorouracil, irinotecan hydrochloride). To examine this, a multi-institution trial has begun to analyze FOLFIRI plus regorafenib compared to FOLFIRI plus placebo. The trial has accrued 50 patients to this point.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine